Assessment of Precision Irradiation in Early NSCLC and Interstitial Lu
Research type
Research Study
Full title
Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (ASPIRE-ILD)
IRAS ID
273931
Contact name
Stephen Harrow
Contact email
Sponsor organisation
London Health Sciences Centre (LHSC)
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
, GN20ON550
Duration of Study in the UK
8 years, 1 months, 17 days
Research summary
Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (ASPIRE-ILD). The standard treatment for early lung cancer that cannot be surgically removed is a type of radiation treatment called ‘stereotactic body radiotherapy’, or SBRT for short. SBRT delivers high-dose, precise radiation in 1-3 weeks of treatments. SBRT usually has mild side effects and is successful in controlling the cancer in about 8 out of 10 patients. However, previous studies have shown that participants with interstitial lung disease (ILD) have a higher chance of experiencing a side effect where their breathing becomes worse in the months after radiation treatment. In high-risk participants, the worsening in breathing can result in death with a chance of up to 1 in 7. However, some studies have shown this risk to be much lower but without treatment, lung cancer can also become rapidly fatal, usually within less than a year.
In this study we are investigating SBRT in patients with non-small cell lung carcinoma with co-existent interstitial lung disease, to determine oncologic and toxicity outcomes. This study is for patients that have been diagnosed with Non-small cell lung cancer T1-T2 No Mo and Fibrotic interstitial lung disease. These will be patients that are not suitable for surgery. The uncertainty of the response to SBRT for patients with ILD is why this is an important research study.
REC name
West of Scotland REC 1
REC reference
20/WS/0175
Date of REC Opinion
14 Dec 2020
REC opinion
Further Information Favourable Opinion